Research programme: memantine reformulations - NeuroMolecular Pharmaceuticals

Drug Profile

Research programme: memantine reformulations - NeuroMolecular Pharmaceuticals

Alternative Names: Memantine reformulations - NeuroMolecular

Latest Information Update: 21 Feb 2008

Price : $50

At a glance

  • Originator NeuroMolecular Pharmaceuticals
  • Class Amines; Analgesics; Antidementias; Antiparkinsonians; Antispastics; Antitussives; Organic bridged compounds; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Research CNS disorders

Most Recent Events

  • 21 Feb 2008 NeuroMolecular Pharmaceuticals is seeking partnership opportunities for this research programme (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top